Tacrolimus (Graceptor (R)) for GVHD prophylaxis after allogeneic stem cell transplantation.

Trial Profile

Tacrolimus (Graceptor (R)) for GVHD prophylaxis after allogeneic stem cell transplantation.

Completed
Phase of Trial: Phase II

Latest Information Update: 11 May 2015

At a glance

  • Drugs Tacrolimus (Primary)
  • Indications Graft-versus-host disease
  • Focus Pharmacokinetics
  • Most Recent Events

    • 08 May 2015 Status changed from recruiting to completed as reported by University Hospital Medical Information Network - Japan record.
    • 06 Oct 2009 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top